Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield SC prior auth criteria | Op…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Actimmune (interferon gamma-1b) and related specialty drug prior authorization criteria (partial)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Portion of the payer's specialty drug prior authorization criteria listing products (including Actimmune and several biologics) with indications, required medical information, prescriber and coverage-duration rules affecting providers submitting PA requests for these products.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActimmune and related specialty drug prior authorization criteria (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionSubmit prior authorization with required diagnostic documentation and evidence of prerequisite trials where specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12Actimmune coverage duration (months)
    6Typical initial biologic approval
    >=10Products in extract
    12

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Common reauth duration (months)
    >=1000HES eosinophil threshold

    Coverage Criteria (Initial and Continuation Rules)

    Actimmune coverage criteria

    Covered when ALL of the following are met

    Actimmune indication: Diagnosis of chronic granulomatous disease (CGD) OR severe malignant osteopetrosis (SMO)

    Required medical information: diagnosis of CGD or SMO

    Coverage duration: Approve for 12 months

    Continuation of prior therapy may be approved

    Adalimumab-class biologics coverage criteria (examples from extract)

    Covered when indication-specific requirements are met

    Rheumatoid arthritis (initial): Diagnosis of moderately to severely active rheumatoid arthritis AND trial and failure, contraindication, or intolerance to one conventional therapy (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses for a minimum of 3 months3 months trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months

    Polyarticular juvenile idiopathic arthritis (PJIA) (initial): Diagnosis of moderately to severely active PJIA AND trial and failure, contraindication, or intolerance to methotrexate or leflunomide at maximally tolerated doses for a minimum of 6 weeks6 weeks trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months

    Plaque psoriasis (initial): Diagnosis of moderate to severe chronic plaque psoriasis AND one of: BSA >=3% OR severe scalp OR palmoplantar/facial/genital involvement AND trial and failure, contraindication, or intolerance to topical therapies (minimum 30-day supply; 14 days for topical corticosteroids)BSA >=3%

    Prescribed by or in consultation with a dermatologist; initial coverage 6 months; reauth 12 months

    Ankylosing spondylitis (initial): Diagnosis of active ankylosing spondylitis AND minimum one-month trial and failure, contraindication, or intolerance to one NSAID at maximally tolerated doses1 month trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months

    Crohn's disease (initial): Diagnosis of moderately to severely active Crohn's disease AND one of: frequent diarrhea/abdominal pain, >=10% weight loss, complications (eg, obstruction, fever, abdominal mass), abnormal labs (eg, CRP), OR Crohn's Disease Activity Index (CDAI) >220CDAI >220

    Prescribed by or in consultation with a gastroenterologist; initial coverage 6 months; reauth 12 months

    Adbry (dupilumab) coverage criteria (partial)

    Covered when ALL of the following are met

    Atopic dermatitis (initial): Diagnosis of moderate to severe atopic dermatitis AND involvement of >=10% body surface area (BSA) OR SCORAD >=25BSA >=10% OR SCORAD >=25

    Trial and failure, contraindication, or intolerance to at least two topical therapies including a medium or higher potency topical corticosteroid (minimum 30-day supply; 14-day supply for topical corticosteroids); patient age >=12 years; prescribed by or in consultation with a dermatologist or allergist/immunologist; initial coverage 6 months; reauth 12 months

    Age restriction: Patient is 12 years of age or older for initial therapyage >=12 years

    Prescriber: dermatologist or allergist/immunologist

    Pulmonary hypertension therapies (partial)

    Covered when ALL of the following are met

    PAH initial: Diagnosis of pulmonary arterial hypertension (PAH) AND symptomatic disease AND either: (A) diagnosis confirmed by right heart catheterization OR (B) patient is currently on therapy for PAH

    Prescribed by or in consultation with a pulmonologist or cardiologist; initial coverage 6 months; reauth 12 months

    CTEPH initial: Either (A) diagnosis of inoperable or persistent/recurrent CTEPH AND CTEPH is symptomatic, OR (B) patient is currently on therapy for CTEPH

    Prescribed by or in consultation with a pulmonologist or cardiologist; initial coverage 6 months; reauth 12 months

    Adempas Initial criteria

    Adempas (riociguat) coverage for PAH or CTEPH

    Initial PAH: Diagnosis of PAH AND PAH is symptomatic AND (A) diagnosis confirmed by right heart catheterization OR (B) patient is currently on any therapy for PAH.

    Prescribed by or in consultation with pulmonologist or cardiologist; Initial coverage duration 6 months; reauth 12 months.

    Initial CTEPH: Either (A) both: diagnosis of inoperable or persistent/recurrent CTEPH AND CTEPH is symptomatic OR (B) patient is currently on any therapy for the diagnosis of CTEPH.

    Prescribed by or in consultation with pulmonologist or cardiologist; Initial coverage duration 6 months; reauth 12 months.

    Afinitor Indications

    Afinitor (everolimus) coverage by indication

    SEGA with TSC: Diagnosis of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex that requires therapeutic intervention

    Patient age >=1 year for SEGA; coverage duration 12 months

    Renal cell carcinoma: Diagnosis of advanced renal cell carcinoma AND trial and failure, contraindication, or intolerance to sunitinib (SUTENT) or sorafenib (NEXAVAR)

    Coverage duration 12 months

    Breast cancer: Diagnosis of advanced hormone receptor-positive, HER2-negative breast cancer AND trial and failure, contraindication, or intolerance to letrozole (FEMARA) or anastrozole (ARIMIDEX)

    Coverage duration 12 months

    pNET and other NETs: Diagnosis of progressive pancreatic neuroendocrine tumor (pNET) or well-differentiated non-functional GI or lung NET with unresectable, locally advanced or metastatic disease

    Aimovig Initial criteria

    Aimovig (erenumab) coverage for migraine prevention

    Episodic migraine (initial): Diagnosis of episodic migraine AND >=4 migraine days per month AND patient is >=18 years old>=4 days/month

    Initial coverage 6 months; reauth 12 months; medication will not be used in combination with another CGRP inhibitor

    Chronic migraine (initial): Diagnosis of chronic migraine AND medication overuse headache considered and offending medications discontinued AND >=8 migraine days per month AND patient is >=18 years old>=8 days/month

    Initial coverage 6 months; reauth 12 months; monitor for medication overuse headache; not used with another CGRP inhibitor

    Prolastin (AAT) criteria

    Alpha-1 proteinase inhibitor (Prolastin-C) coverage for AAT deficiency

    AAT deficiency initial: Diagnosis of congenital AAT deficiency AND emphysema AND continued conventional treatment for emphysema AND (1) homozygous PiZZ or equivalent OR (2) other rare genotypes associated with pre-treatment serum AAT <11 µM/L; pre-treatment circulating serum AAT <11 µM/L (or lab equivalents)AAT <11 µM/L

    Coverage duration initial and reauth 12 months; reauth requires positive clinical response

    Ampyra Initial Therapy

    Ampyra (dalfampridine) — MS (Initial)

    Ampyra initial coverage: Diagnosis of multiple sclerosis AND physician confirmation that patient has difficulty walking (eg, timed 25-foot walk) AND one of: EDSS score ≤7 OR not restricted to using a wheelchairEDSS ≤7

    Prescribed by or in consultation with a neurologist; coverage duration initial 6 months, reauth 12 months

    Arformoterol Coverage

    Arformoterol Tartrate — COPD

    Arformoterol coverage: Diagnosis of COPD AND used for maintenance treatment of bronchoconstriction in patients with COPD (including chronic bronchitis and emphysema)

    Coverage duration 12 months

    Arikayce Initial Therapy

    Arikayce — MAC lung disease

    Arikayce coverage: Diagnosis of Mycobacterium avium complex (MAC) lung disease AND used as part of a combination antibacterial drug regimen AND patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen>=6 months multidrug regimen without >=2 negative sputum cultures

    Prescribed by or in consultation with an infectious disease specialist; coverage duration 12 months

    Augtyro Coverage

    Augtyro — NSCLC and NTRK/ROS1 indications

    Augtyro coverage: Diagnosis of NSCLC with ROS1 rearrangement OR diagnosis of solid tumor with NTRK gene fusion AND disease is locally advanced, metastatic, or unresectable AND either disease progressed following previous treatment or no satisfactory alternative treatments exist

    Coverage duration 12 months; approve continuation of prior therapy

    Austedo Coverage

    Austedo — Huntington's chorea and Tardive Dyskinesia

    Austedo indications: Chorea associated with Huntington's disease OR tardive dyskinesia

    For tardive dyskinesia: persistent symptoms despite trial of dose reduction/tapering/discontinuation of offending medication OR not a candidate for such trial; prescriber restrictions apply; coverage duration initial/reauth 12 months

    Avmapki Fakzynja Coverage

    Avmapki Fakzynja — KRAS-mutant tumors

    Avmapki Fakzynja coverage: Presence of a KRAS mutation detected by an FDA-approved or CLIA-approved test AND patient has received prior systemic therapy (e.g., chemotherapy)

    Continuation of prior therapy may be approved; prerequisite Part D drug required

    Avtozma Coverage (RA, GCA, SJIA, PJIA, SSc-ILD)

    Avtozma products — Rheumatologic indications

    Avtozma RA/PJIA initial: Diagnosis of moderately to severely active RA or active PJIA AND either TF/C/I to two specified agents (eg, etanercept, a formulary adalimumab, abatacept, upadacitinib, tofacitinib) OR attestation that trials are inappropriate OR continuation of prior therapy

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months; prerequisite Part D drug required per section

    Avtozma SJIA initial: Diagnosis of active systemic juvenile idiopathic arthritis AND minimum 1-month trial of an NSAID at maximally tolerated dose1 month NSAID trial

    Prescribed by or in consultation with a rheumatologist; initial coverage 6 months; reauth 12 months

    Avtozma SSc-ILD initial: Diagnosis of systemic sclerosis-associated interstitial lung disease with exclusion of other causes AND supportive HRCT or lung biopsy pattern consistent with SSc-ILD

    Prescribed by or in consultation with a specialist; initial coverage 6 months; reauth 12 months

    Actimmune-related Coverage Durations and Reauthorization

    Coverage durations and reauthorization requirements for selected Actimmune-related indications

    Initial coverage (selected Actimmune-related indications): Initial coverage duration for RA, GCA, SJIA, PJIA, SSc-ILD is 6 months

    Reauthorization requires demonstration of positive clinical response

    Reauthorization coverage duration is 12 months and requires demonstration of positive clinical response (eg, reduction in swollen/tender joint count or symptom improvement); prerequisite Part D drug required where specified

    No explicit exclusion conditions are provided in the excerpted criteria listings. The policy text for Actimmune and numerous specialty agents in this extract mark Exclusion Criteria or Off‑Label Uses as "N/A" for many entries, and where exclusions are specified they are narrow and product‑specific (examples: ciclopirox excludes lunula/matrix involvement; cinryze and icatibant are not to be used in combination with other approved prophylactic or acute HAE treatments; pyrimethamine is not authorized for malaria). Refer to the individual product sections for any named exclusions; absent such language, the extract does not list broad exclusion rules applicable across products.

    Product and Clinical Codes / Thresholds

    Products listed (partial)NDC | product
    Actimmune INJ 100MCG/0.5MLActimmune product listing as affected product
    Products listed (adalimumab biosimilars)product
    Adalimumab-aaty 1-pen KitAdalimumab-aaty product
    Adalimumab-adbmAdalimumab-adbm product
    Products listed (dupilumab biosimilar/brand)product
    AdbryAdbry product listing
    Products listed (PAH therapies)product
    AlyqAlyq product listing (tadalafil brand)
    Tadalafil TABS 20MGTadalafil 20 mg tablet
    Formulary identifiersmixed
    Formulary ID: 26218Afinitor formulary identifier and version
    Covered drug productsNDC|ProductCovered
    Cosentyx INJ 150MG/MLProduct listed in policy
    Cosentyx INJ 75MG/0.5MLProduct listed in policy
    Cosentyx Sensoready PenProduct listed in policy
    Cosentyx UnoreadyProduct listed in policy
    Cosentyx INJ 125MG/5MLIV formulation listed
    Formulary identifiersmixed
    Formulary ID: 26218Formulary identifier listed in the document
    Products listed (examples)mixed
    Dupixent INJ 200MG/1.14MLDupixent injection presentation listed in product section
    Dupixent INJ 300MG/2MLDupixent injection presentation listed in product section
    Products listedmixed
    Ebglyss 2Ebglyss product referenced
    Products listedmixed
    EmgalityEmgality product referenced
    Atopic dermatitis: key thresholds
    Atopic dermatitis severityBSA >= 10% OR SCORAD >= 25
    Required prior topical therapyTrial and failure (or CI/intolerance) to at least two topical therapies including a medium-or-higher potency topical corticosteroid (30‑day supply; 14 days for topical corticosteroids)
    Age restrictionPatient is >= 12 years of age for initial therapy
    Crohn's disease: activity index
    CDAI threshold

    Prior Authorization, Required Documentation, and Denial Risks

    Prior Authorization

    Actimmune prior authorization required

    Actimmune requires prior authorization. Submit documentation confirming diagnosis of chronic granulomatous disease (CGD) or severe malignant osteopetrosis (SMO); approvals are issued for 12 months and continuation of prior therapy may be approved.

    Prior Authorization

    Follow indication-specific PA requirements for biologics

    Biologic and specialty products listed require prior authorization per product-specific criteria — include the indication-specific diagnosis, required prior therapy trials (TF/C/I) or rationale why trials are inappropriate, prescriber specialty or consultation as indicated, and the coverage duration specified for the product/indication.

    • Document disease-specific measures (e.g., BSA, CDAI, eosinophil counts) and prior trial/failure, contraindication, or intolerance to specified conventional therapies.
    • Prescriber must be the required specialist or include documentation of specialist consultation when required.
    • Include duration requested consistent with initial or reauthorization periods noted in the product criteria.

    Background and Scope

    This extract compiles prior authorization requirements for specialty immunology and rheumatology drugs and related products. For the biologic and specialty agents shown, approvals are indication‑specific and typically require documented diagnosis, prescriber specialty or consultant involvement (eg, rheumatologist, dermatologist, pulmonologist), and evidence of prior standard therapy trials or intolerance when specified (commonly described as trial and failure, contraindication, or intolerance — TF/C/I).

    Coverage durations and reauthorization expectations are routinely specified: initial approvals for many biologic indications are commonly 6 months with reauthorization contingent on demonstration of positive clinical response and typically renewed for 12 months. Providers submitting PA requests should include the required objective disease measures, prior therapy history and durations, and any molecular or laboratory test results called for by the product‑specific criteria.

    Definitions and Clinical Thresholds

    TF/C/I — definition
    TF/C/I definitionTrial and failure, contraindication, or intolerance (TF/C/I) to specified conventional therapies
    PurposeUsed as prerequisite therapy requirement across multiple biologic indications
    Example therapiese.g., methotrexate, leflunomide, sulfasalazine for RA where specified
    CDAI — referenced threshold
    CDAI referenceCrohn's Disease Activity Index (CDAI) > 220 used as disease severity criterion
    ContextApplied for Crohn's disease when documenting moderately to severely active disease
    Prescriber

    Policy Version & Revision History

    2026-08-01effective_dateLatest

    Policy effective date set to 2026-08-01.

    2026-07-02last_review

    Policy last reviewed on 2026-07-02.

    2026-07-02next_review

    Next review scheduled for 2026-07-02.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyActimmune and related specialty drug prior authorization criteria (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewJul 2, 2026
    Next Review DateJul 2, 2026
    Key ActionSubmit prior authorization with required diagnostic documentation and evidence of prerequisite trials where specified.
    SourceLink
    On This Page
    Coverage Criteria (Initial and Continuation Rules)Product and Clinical Codes / ThresholdsPrior Authorization, Required Documentation, and Denial RisksBackground and ScopeDefinitions and Clinical ThresholdsPolicy Version & Revision History

    Coverage duration 12 months

    Renal angiomyolipoma: Diagnosis of renal angiomyolipoma associated with TSC

    Coverage duration 12 months

    CDAI > 220
    Other severity markersFrequent diarrhea/abdominal pain, >=10% weight loss, complications (eg, obstruction, fever, abdominal mass), or abnormal labs (eg, CRP)
    PrescriberPrescribed by or in consultation with a gastroenterologist
    Plaque psoriasis: BSA threshold
    Plaque psoriasis BSA thresholdBSA >= 3%
    Alternate severity criteriaSevere scalp psoriasis or palmoplantar/facial/genital involvement qualify as moderate-to-severe disease
    Topical trial requirementMinimum trial and failure of topical therapies (minimum 30 days; 14 days for topical corticosteroids)
    Migraine prevention: monthly-day thresholds
    Migraine frequency (episodic)>= 4 migraine days per month (EM)
    Migraine frequency (chronic)>= 8 migraine days per month (CM)
    Age restriction and monotherapy rulePatients must be >=18 years; not to be used in combination with another injectable CGRP inhibitor
    Alpha-1 antitrypsin (AAT) threshold
    Serum AAT pre-treatment thresholdPre-treatment circulating serum AAT < 11 µM/L (corresponds to <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry)
    Genotype criteriaHomozygous PiZZ or other rare genotypes associated with low AAT (eg, Pi(Malton)) may qualify
    Clinical requirementDiagnosis of congenital AAT deficiency with emphysema and continued conventional treatment for emphysema
    EDSS threshold (dalfampridine/Ampyra)
    EDSS threshold for dalfampridineEDSS ≤ 7
    Alternative walking criterionNot restricted to using a wheelchair if EDSS not measured; physician confirmation of difficulty walking required
    PrescriberPrescribed by or in consultation with a neurologist
    MAC lung disease: sputum culture requirement
    MAC sputum culture requirementPatient did not achieve ≥2 negative sputum cultures after ≥6 consecutive months of a multidrug background regimen
    Combination regimenMust be used as part of a combination antibacterial drug regimen for MAC lung disease
    PrescriberPrescribed by or in consultation with an infectious disease specialist
    SJIA: NSAID trial requirement
    SJIA NSAID trial durationMinimum 1 month at maximally tolerated dose
    PrescriberPrescribed by or in consultation with a rheumatologist
    Coverage durationsInitial coverage 6 months; reauthorization 12 months with demonstrated clinical response
    Platelet threshold (selected indications)
    Platelet count requirement (Ayvakit AdvSM/ISM)>= 50 x 10^9/L
    Indication-specific noteRequired for AdvSM and ISM indications; prescriber and diagnostic documentation required
    Coverage duration12 months
    SLE: autoantibody thresholds
    Autoantibody requirement for SLE (Benlysta)ANA >= 1:80 OR anti-dsDNA >= 30 IU/mL
    Concomitant therapy requirementPatient must be currently receiving at least one standard-of-care treatment (eg, antimalarials, corticosteroids, or immunosuppressants)
    PrescriberPrescribed by or in consultation with a rheumatologist for SLE
    Polycythemia vera: Hgb/Hct thresholds
    Hemoglobin / Hematocrit thresholds (PV)Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women) OR Hematocrit >49% (men) or >48% (women)
    Genetic/biochemical adjunctPresence of JAK2 V617F or exon 12 mutation, or subnormal serum erythropoietin may be required
    Coverage duration12 months
    Baseline ferritin and transfusion thresholds
    Baseline ferritin for iron overload> 1,000 mcg/L
    Transfusion volume requirement>= 100 mL/kg packed RBCs for transfusional iron overload indication
    LIC threshold (NTDT)>= 5 mg Fe/g dw
    Eosinophil thresholds (asthma / HES)
    Eosinophil threshold (asthma)>= 150 cells/mcL
    Fasenra HES eosinophil threshold>= 1000 cells/mcL
    HES additional requirementsRule out non-hematologic secondary causes; FIP1L1-PDGFRA negative; trial/failure of corticosteroid or cytotoxic/immunosuppressive therapy
    Fasenra: asthma eosinophil threshold
    Fasenra eosinophil threshold (asthma)>= 150 cells/microliter
    Prescriber and controller therapy requirementPrescribed by or in consultation with pulmonologist or allergist/immunologist; patient on appropriate inhaled corticosteroid/controller regimen (eg, high‑dose ICS or specified ICS/LABA)
    Coverage durationsInitial 6 months (asthma); reauthorization 12 months with positive clinical response
    Fasenra: HES eosinophil threshold
    Fasenra eosinophil threshold (HES)>= 1000 cells/microliter pre-treatment
    Diagnostic exclusionsExclude secondary non-hematologic causes and confirm FIP1L1-PDGFRA negative
    Prior therapy requirementTrial and failure/CI/intolerance to corticosteroid or cytotoxic/immunosuppressive therapy required
    Actimmune: adequate iron stores
    Actimmune iron-store requirementFerritin > 100 mcg/L AND TSAT > 20%
    ApplicabilityRequired for Actimmune use in CKD, HIV, chemotherapy, preop, MDS, and HCV indications per criteria
    Documentation noteLab confirmation must be supplied to support adequate iron stores prior to authorization
    Prior Authorization

    Adempas: specialist prescriber and time-limited approval

    Adempas (riociguat) requires prior authorization; initial approvals are for 6 months with reauthorization for 12 months. Prescriber must be or consult with a pulmonologist or cardiologist and documentation must show PAH or inoperable/persistent CTEPH per the criteria (right heart catheterization confirmation or current PAH/CTEPH therapy when applicable).

    Prior Authorization

    Afinitor PA and prior‑therapy documentation

    Afinitor (everolimus) requires prior authorization. Include indication-specific documentation and, where specified (eg, RCC or breast cancer), evidence of trial and failure, contraindication, or intolerance to the named prior agents; typical coverage duration is 12 months and continuation of prior therapy may be approved.

    Prior Authorization

    Aimovig: migraine frequency, no CGRP combination, and durations

    Aimovig (erenumab) requires prior authorization. For initial approval (6 months) and reauthorization (12 months) document diagnosis of episodic migraine (≥4 days/month) or chronic migraine (≥8 days/month), consideration and discontinuation of medication overuse when applicable, and that the patient is not using another CGRP inhibitor.

    Prior Authorization

    Ampyra: MS diagnosis, walking impairment, and EDSS requirement

    Ampyra (dalfampridine) requires prior authorization with physician confirmation of an MS diagnosis and objective evidence of difficulty walking (eg, timed 25-foot walk). Document EDSS ≤7 or that the patient is not wheelchair‑restricted; prescriber is or consulted neurologist. Initial coverage is 6 months; reauthorization 12 months.

    Prior Authorization

    Arformoterol PA: COPD diagnosis and 12‑month duration

    Arformoterol tartrate requires prior authorization for maintenance treatment of COPD. Provide documentation of COPD diagnosis; typical coverage duration is 12 months.

    Prior Authorization

    Arikayce: MAC diagnosis and failed ≥6‑month multidrug regimen

    Arikayce requires prior authorization for Mycobacterium avium complex (MAC) lung disease. Document MAC diagnosis, that the drug will be used as part of a combination antibacterial regimen, and that the patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug therapy; coverage duration 12 months.

    Prior Authorization

    Augtyro PA: required genomic evidence and prior‑therapy status

    Augtyro prior authorization requires tumor genomic evidence (ROS1 rearrangement or NTRK gene fusion) and documentation that disease is locally advanced/metastatic or unresectable and has progressed after prior therapy or lacks satisfactory alternatives; coverage duration 12 months and continuation of prior therapy may be approved.

    Prior Authorization

    Austedo PA: diagnosis and trial/reduction documentation for TD

    Austedo requires prior authorization for chorea of Huntington's disease and tardive dyskinesia. Document the diagnosis and either a trial of dose reduction/tapering of offending medication (or rationale why not feasible) for TD; prescriber specialty varies by indication; coverage initial and reauth 12 months.

    Prior Authorization

    Avmapki Fakzynja: KRAS mutation and prior systemic therapy required

    Avmapki Fakzynja requires prior authorization with documentation of a KRAS mutation detected by an FDA‑approved or CLIA‑approved test and evidence of prior systemic therapy; continuation of prior therapy may be approved.

    Prior Authorization

    Avtozma PA: indication‑specific trials and rheumatology consult

    Avtozma (and Avtozma SC) prior authorization requires indication‑specific diagnoses (RA, GCA, SJIA, PJIA, SSc‑ILD) and documentation of required prior therapy trials or attestation that trials are inappropriate; prescriber must be or consult a rheumatologist for many indications; initial coverage 6 months, reauthorization 12 months.

    Prior Authorization

    Actimmune‑related indications: 6‑month initial, 12‑month reauth

    For selected Actimmune‑related indications (RA, GCA, SJIA, PJIA, SSc‑ILD) prior authorization is required with initial coverage of 6 months and reauthorization of 12 months; reauthorization requires demonstration of positive clinical response (eg, reduced swollen/tender joint count).

    Prior Authorization

    Ayvakit: required mutation/platelet documentation and 12‑month duration

    Ayvakit coverage is authorized for 12 months. Document the diagnosis (eg, unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V, or AdvSM/ISM with platelet count ≥50 ×10^9/L); criteria allow continuation of prior therapy and do not require a prerequisite Part D drug.

    Prior Authorization

    Balversa: FGFR3 testing and 12‑month coverage

    Balversa coverage duration is 12 months. Prior authorization requires documentation of locally advanced or metastatic urothelial carcinoma with a susceptible FGFR3 alteration detected by an FDA‑approved or CLIA‑approved test and prior systemic therapy/progression when specified.

    Prior Authorization

    Benlysta PA: autoantibody positivity, SOC therapy, and 6‑month duration

    Benlysta requires prior authorization; initial and reauthorization approvals are for 6 months. For initiation document active SLE with autoantibody positivity (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL) and current use of at least one standard‑of‑care therapy; reauthorization requires demonstration of positive clinical response.

    Prior Authorization

    Bronchitol PA: CF diagnosis, BTT, and benefit‑dependent reauth

    Bronchitol requires prior authorization for cystic fibrosis initial use; include CF diagnosis and documentation that the patient passed the Bronchitol Tolerance Test (BTT). Initial coverage is 6 months; reauthorization 12 months contingent on clinical benefit.

    Prior Authorization

    Brukinsa PA: indication‑specific prior therapy documentation

    Brukinsa requires prior authorization with coverage duration 12 months. Document diagnosis and prior therapy history specific to the labeled indication (eg, at least one prior therapy for MCL or prior anti‑CD20 regimen for MZL); continuation of prior therapy may be approved.

    Prior Authorization

    Cablivi PA: aTTP IV administration and 3‑month coverage

    Cablivi requires prior authorization for aTTP; document aTTP diagnosis, that the first dose is/will be administered as a bolus IV by a healthcare provider, concomitant immunosuppressive therapy/plasma exchange status, and note coverage duration is 3 months.

    Prior Authorization

    Cabometyx PA: diagnosis, prior VEGFR therapy where specified, 12 months

    Cabometyx requires prior authorization with coverage duration 12 months. Provide diagnosis (RCC, HCC, DTC, NET) and prior therapy history — some indications require trial/failure of sorafenib or other VEGFR‑targeted therapies; continuation of prior therapy may be approved.

    Prior Authorization

    Calquence PA: diagnosis and prior‑therapy status required

    Calquence requires prior authorization with coverage duration 12 months. Include diagnosis and prior therapy status (eg, treatment‑naïve and HSCT ineligible vs prior therapy) as indicated by the criteria.

    Prior Authorization

    Caplyta PA: prerequisite antipsychotic trials and 12‑month coverage

    Caplyta requires prior authorization with coverage duration 12 months. Document diagnosis and trial/failure, contraindication, or intolerance to the specified oral generic atypical antipsychotics per indication.

    Prior Authorization

    Caprelsa PA: metastatic MTC documentation and 12‑month duration

    Caprelsa requires prior authorization with coverage duration 12 months; document metastatic or unresectable medullary thyroid cancer and evidence of symptomatic or progressive disease per criteria.

    Prior Authorization

    Cayston PA: CF age restriction (≥7 yrs) and reauth benefit requirement

    Cayston requires prior authorization; initial CF use is restricted to patients ≥7 years and reauthorization requires demonstration of benefit (eg, fewer pulmonary exacerbations).

    Prior Authorization

    Cerdelga PA: Gaucher diagnosis and CYP2D6 testing

    Cerdelga requires prior authorization with coverage duration 12 months and documentation of Gaucher disease type 1 plus CYP2D6 metabolizer status (EM/IM/PM) as detected by an FDA‑cleared test; age ≥18 for Gaucher disease.

    Documentation Required

    Cerdelga (Gaucher disease) — required genotype documentation

    For Gaucher disease, ensure documentation includes diagnosis of type 1 Gaucher disease and CYP2D6 metabolizer status (extensive, intermediate, or poor) per an FDA‑cleared test; coverage duration is 12 months.

    Prior Authorization

    Cholbam PA: diagnostic testing required and 4‑month initial approval

    Cholbam prior authorization requires diagnostic confirmation for bile acid synthesis disorders (abnormal urinary bile acid analysis by mass spectrometry or molecular genetic testing); initial approval is 4 months with reauthorization for 12 months contingent on clinical response.

    Prior Authorization

    Ciclopirox PA: confirm onychomycosis, terbinafine trial, 48‑week duration

    Ciclopirox prior authorization requires confirmation of onychomycosis (KOH, culture, or histology), absence of lunula involvement, and documented trial/failure/contraindication/intolerance to oral terbinafine (minimum 6 weeks for fingernails, 12 weeks for toenails); coverage duration 48 weeks.

    Prior Authorization

    Cinryze PA: HAE lab confirmation, specialist prescriber, and age limit

    Cinryze prior authorization for HAE prophylaxis requires laboratory confirmation of HAE (low C4 with low C1‑INH antigenic or functional level, or confirmatory genetic/family history for HAE‑nl‑C1INH), prescriber is or consults an immunologist/allergist, age ≥6 years for prophylaxis, and reauthorization requires evidence of positive clinical response; not to be used with other prophylactic HAE treatments.

    Prior Authorization

    Cobenfy PA: intolerance to two listed antipsychotics required

    Cobenfy prior authorization requires intolerance to two listed oral generic atypical antipsychotics before approval; continuation of prior therapy may be approved.

    Prior Authorization

    Cometriq PA: metastatic MTC diagnosis and 12‑month coverage

    Cometriq prior authorization requires diagnosis of metastatic medullary thyroid cancer; coverage duration 12 months and continuation of prior therapy may be approved.

    Prior Authorization

    Copiktra PA: relapsed/refractory CLL/SLL and ≥2 prior therapy trials

    Copiktra prior authorization requires CLL or SLL diagnosis that is relapsed/refractory and documentation of trial and failure, contraindication, or intolerance to at least two prior therapies for CLL/SLL.

    Prior Authorization

    Cosentyx PA: severity, prior therapy trials, and prescriber restrictions

    Cosentyx prior authorization requires documentation of diagnosis and severity (eg, plaque psoriasis with ≥3% BSA or special-site involvement) and prior trial/failure/contraindication/intolerance to topical therapies or specified systemic/biologic agents as listed for each indication; prescriber specialty/consultation and coverage durations vary by formulation and indication.

    Prior Authorization

    Cosentyx SC/IV: prior‑therapy and specialist documentation required

    Prior authorization for Cosentyx SC and IV formulations requires evidence of diagnosis, required prior therapy trials, and prescriber specialty or consultation where specified; IV formulation may require TF/C/I to two listed agents unless continuing prior therapy.

    Prior Authorization

    Roflumilast PA: COPD exacerbation history and two‑therapy step requirement

    Roflumilast (DALIRESP) requires prior authorization; document COPD diagnosis, history of exacerbations (systemic steroids/antibiotics/hospitalization), and trial/failure/intolerance/contraindication to two prior COPD therapies; coverage duration 12 months.

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Prescribed by or in consultation with a gastroenterologist
    Alpha-1 antitrypsin deficiency — diagnostic threshold
    AAT deficiency criteriaDiagnosis of congenital AAT deficiency with emphysema AND pre-treatment circulating serum AAT < 11 µM/L
    Genotype examplesHomozygous PiZZ or other rare genotypes associated with low AAT (eg, Pi(Malton, Malton), Pi(SZ))
    Coverage durationInitial and reauthorization coverage 12 months; reauth requires positive clinical response
    Pulmonary arterial hypertension — confirmation
    PAH diagnostic confirmationPulmonary arterial hypertension diagnosis often requires symptomatic disease AND confirmation by right heart catheterization OR current PAH therapy
    PrescriberPrescribed by or in consultation with pulmonologist or cardiologist
    Coverage duration noteAdempas initial coverage 6 months; reauth 12 months
    EDSS — definition and use
    EDSS definitionExpanded Disability Status Scale (EDSS) — threshold used: ≤ 7
    Clinical useAlternative to wheelchair restriction to assess eligibility for dalfampridine
    DocumentationPhysician confirmation of difficulty walking (eg, timed 25‑foot walk)
    CYP2D6 metabolizer testing (Cerdelga)
    CYP2D6 metabolizer statusCYP2D6 metabolizer classification (EM/IM/PM) by FDA-cleared test is required for Cerdelga use in Gaucher disease
    Age restrictionPatient >= 18 years for Gaucher disease indication
    Coverage duration12 months
    Hereditary angioedema — diagnostic confirmation
    HAE diagnostic confirmationEither low C4 with low C1‑INH antigenic or functional level OR normal C4/C1‑INH with confirmatory genetic mutation or family history
    Use limitationNot used in combination with other prophylactic HAE treatments; prescriber is or consults immunologist/allergist
    Age for prophylaxisPatient >= 6 years for prophylaxis initial therapy
    Molecular diagnostic testing — requirement
    Molecular diagnostic requirementPresence of specified mutations (eg, HER2/ERBB2 activating mutations, ROS1 rearrangement) must be detected by an FDA‑approved or CLIA‑approved test for targeted oncology agents
    ExamplesHernexeos/Hyrnuo: HER2 activating mutations; Ibtrozi: ROS1 rearrangement; Gavreto: RET fusion detected by FDA‑approved or CLIA test
    Coverage implicationLack of documented mutation by approved testing may trigger denial